COPD Leukopak

About COPD Leukopak

COPD Leukopak for Chronic Airway Inflammation Research

LeukoCore COPD Leukopak biospecimens are collected from IRB-consented donors clinically diagnosed with chronic obstructive pulmonary disease through IRB-approved apheresis procedures. Each peripheral blood leukopak contains large quantities of leukocytes including peripheral blood mononuclear cells, is processed and shipped within 24 hours of collection, and is available fresh or cryopreserved for immune profiling, cell-based assays and drug development in COPD.

Why COPD Leukopak for Airway Inflammation Research

COPD is a chronic inflammatory airway disease rather than an autoimmune one. Sustained inhalational injury drives recruitment of neutrophils and macrophages into the airways and parenchyma; oxidative stress amplifies the response, and the resulting protease-antiprotease imbalance degrades elastin and other structural matrix. The circulating leukocytes that feed and sustain that infiltrate are exactly what an apheresis leukopak delivers, and at a scale no venipuncture draw can match.

• Neutrophils in bulk — apheresis collection yields enough granulocytes and mononuclear cells to support neutrophil chemotaxis, degranulation and elastase-release assays that are impractical from small draws.
• Monocyte and macrophage biology — donor monocytes can be differentiated into macrophage models to study impaired phagocytosis, efferocytosis and defective bacterial clearance described in COPD.
• Protease release and matrix degradation — neutrophil elastase and matrix metalloproteinases including MMP-9 and MMP-12 can be measured as functional cellular outputs, not just as circulating concentrations.
• Oxidative burst and redox stress — reactive oxygen species generation and antioxidant handling in disease-state leukocytes can be assayed directly in viable cells.
• Lymphocyte compartment — CD8+ T cells, Th1 and Th17 populations and the eosinophilic subset seen in some donors are all accessible for immunophenotyping and single-cell work.
• Scale for screening — high cell yield from a single well-characterised donor removes donor-to-donor variability across a full assay-development or compound-screening campaign.

Donor Stratification Available

• Airflow limitation severity — donors graded by spirometry-based severity classification where documented
• Clinical phenotype — emphysema-predominant, chronic bronchitis-predominant, and mixed presentations
• Exacerbation history — frequent exacerbators versus stable donors at the time of collection
• Alpha-1 antitrypsin deficiency status — donors with documented deficiency available as a distinct subgroup
• Smoking and exposure history — current smokers, former smokers, and never-smokers with occupational or biomass exposure; treatment status including inhaled corticosteroid and biologic therapy
• Matched healthy controls available, including smoking-matched controls without airflow limitation

Product Features

• Research Use Only (RUO) human COPD leukopaks
• Clinically confirmed COPD donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

De-identified Donor Data

• Verified COPD diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Relevant clinical data including COPD severity (if available)
• Smoking history and exacerbation context reported per lot where captured

Applications

• Neutrophil chemotaxis, degranulation and elastase-release assays
• Monocyte-derived macrophage models of impaired phagocytosis and clearance
• Oxidative burst and redox stress measurement in disease-state leukocytes
• Matrix metalloproteinase production and matrix degradation functional assays
• Immune cell characterisation and deep immunophenotyping in COPD
• Multi-omics studies including single-cell RNA sequencing
• Compound screening and ex vivo pharmacology at scale
• Cell-based assay and cytokine release profiling for anti-inflammatory programmes

Other COPD Specimen Types

• COPD PBMC
• COPD Whole Blood
• COPD Plasma
• COPD Serum
• COPD Bulk Plasma

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

COPD Peripheral Blood Leukopak samples are available fresh or cryopreserved. For pricing, international shipping or regulatory documentation, please contact learnmore@sanguinebio.com to confirm regional compliance and shipping availability. Need a different condition, or want to check current availability across our full leukopak inventory? Visit our human leukopak page to browse other disease-state options and live stock status.